SCHEMBL3014368

SCHEMBL3014368

COc1cccc(Cc2csc(N3CCC(S(=O)(=O)c4ccccc4C#N)CC3)n2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.40
HSD17B10 Q99714 4/20 0.40
ALDH1A1 P00352 3/20 0.40
LMNA P02545 3/20 0.40
HPGD P15428 1/20 0.40
DRD2 P14416 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
KCNH2 Q12809 1/20 0.39
PTPRB P23467 1/20 0.38
USP2 O75604 1/20 0.36
RECQL P46063 1/20 0.36
TP53 P04637 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
GPR6 P46095 1/20 0.36
CTSS P25774 2/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015476 0.93 DRD2 (0.40) MAPTHSD17B10ALDH1A1LMNAHPGD
SCHEMBL3010377 0.91 DRD2 (0.41) MAPTALDH1A1LMNADRD2HTR2A
SCHEMBL3011738 0.89 DRD2 (0.41) ALDH1A1DRD2HTR2AHTR2CKCNH2
SCHEMBL3017560 0.89 DRD2 (0.39) MAPTALDH1A1DRD2HTR2AHTR2C
SCHEMBL3016066 0.88 DRD2 (0.41) DRD2HTR2AHTR2CKCNH2KMT2A
SCHEMBL3016445 0.88 DRD2 (0.43) LMNADRD2HTR2AHTR2CKCNH2
SCHEMBL3011673 0.87 MAPT (0.42) MAPTHSD17B10ALDH1A1LMNAHPGD
SCHEMBL3006777 0.87 MAPT (0.44) MAPTHSD17B10ALDH1A1LMNAHPGD
SCHEMBL3014359 0.87 DRD2 (0.42) MAPTHSD17B10ALDH1A1LMNAHPGD
SCHEMBL3007206 0.87 HTR2A (0.44) MAPTHSD17B10ALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HSD17B10 2553/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.